Sale!

Research Paper on Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients Have a Prognostic Impact

Original price was: ₹21,240.00.Current price is: ₹10,620.00. inc. GST

Research Paper on Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients Have a Prognostic Impact

1 in stock

Description

Title: Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients Have a Prognostic Impact

Abstract: Background. In haematological malignancies, the Wnt signaling pathway was dysregulated. Previous research suggested that serum Galectin-3 levels and lymphoid enhancer factor 1 (LEF1) expression could influence clinical outcomes and clinical parameters in patients with acute myeloid leukemia. However, as far as we are aware, no research has looked at how these two factors may interact to affect AML patients. Aim. In peripheral blood from 69 AML patients, we examined LEF1 expression using real-time qPCR and measured the serum level of Gal.3 using the ELISA technique. We then correlated these results with various clinicopathological patient evaluation criteria, including response, PFS, and OS. Results. Low serum Gal.3 level had better OS (= 0.014) and EFS (= 0.02) compared to high serum Gal.3 level, and high expression (LEF1high) was associated with worse OS (= 0.02) and EFS (= 0.019) than LEF1low. In addition, LEF1high patients are more likely to have favorable risk factors (=0.02) than LEF1low patients and are less likely to have a FLT3-ITD (=0.047) than LEF1low patients. Patients with higher Gal-3 levels have a poorer prognosis (=0.02) compared to those with lower Gal-3 levels, and they are also more likely to have a FLT3-ITD with borderline significance (=0.054). Less likely to carry FLT3-ITD, lower baseline blast percentages, favorable risk, higher CR rate, and shorter time to CR were all observed in combined LEF1high/Gal.3 low patients compared to other groups. When compared to LEF1low expression, the high Gal.3 level group’s OS and EFS improved (20 and 15 months, respectively) (13 and 8 months respectively). Conclusion. We draw the conclusion that serum galectin.3 level assessment is not necessary to determine the risk and outcome of an AML patient with high LEF1 expression.

Paper Quality: SCOPUS / Web of Science Level Research Paper

Subject: Medicine

Sub Category: Hematology

Writer Experience: 20+ Years

Plagiarism Report: Turnitin Plagiarism Report will be less than 10%

Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.

What will I get after the purchase?

A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.

In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.